Plasma Protein Biomarkers in HIV Patients on Opioid Use Disorder Medication

A study from the Philadelphia FIGHT Treatment Center analyzed plasma samples from 43 virally suppressed people with HIV, grouped by opioid use disorder medication status. The dataset likely contains measurements of 12 unique proteins, such as HSP70 and sCD14, identified via the SomaScan platform and ELISA analysis. The data, authored by Livio Azzoni and last updated in April 2026, suggests associations between these biomarkers and risks for kidney disease, heart failure, and dementia.

Use Cases

• Identifying protein signatures associated with opioid use disorder medication in HIV patients based on the 12 differentially expressed proteins.
• Assessing risk for adverse clinical outcomes like kidney disease or dementia based on biomarker levels such as HSP70 and sCD14.
• Comparing immune biomarker profiles between patient groups on methadone, suboxone, and controls.
• Validating proteomic assay findings using corroborative ELISA results mentioned for HSP70, IGLL1, and sCD14.

Strengths

• Includes data from 43 participants with detailed group breakdowns (14 control, 15 SUB, 14 MET).
• Reports mean participant age (48.6 years) and mean ART duration (10.4 years), showing demographic consistency.
• Findings are supported by two analytical methods: SomaScan assay and corroborating ELISA analysis for specific proteins.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The sample size is relatively small (43 participants), which may affect statistical power and generalizability.
• Data is provided in a DOCX file (229.7 KB), which may require extraction and formatting for analysis.

Provenance

Source

figshare, authored by Livio Azzoni.

Collection Method

Plasma samples from participants were analyzed using the SomaScan platform; differential expression was tested with Wilcoxon rank-sum test and beta regression.

Freshness

Last updated 2026-04-28 04:29:21; freshness should be verified.

Geography

Participants were enrolled from the Philadelphia FIGHT Treatment Center, suggesting a U.S.-based study.